Recent Updates
Recently added Catalysts

-107A-01

Phase 2

Pain | Small molecule | Pain |Viatris Inc.|Last Updated: Aug 8, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment114
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04571515Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental PainPHASE2 COMPLETED 114Sep 29, 2020Dec 22, 2020Aug 8, 20221 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Overall Summed Pain Intensity Difference (SPID)
24 hours after the first dose

Participants assessed Pain Intensity (PI) using a 0-10 numeric pain rating scale (NPRS) where 0 is no pain and 10 is worst pain imaginable. PI was assessed 17 times within 24 hours after the first study dose, and immediately before any rescue medication and/or at early termination. The participant's baseline PI was subtracted from the timepoint PI, to derive a Pain Intensity Difference (PID) for each timepoint. Overall Summed Pain Intensity Difference (SPID) measures pain intensity change relative to baseline over the 24 hour period after dosing, and corresponds to the Area Under the Curve (AUC) of the PID. In this study, higher positive Overall SPID indicates better pain improvement. Overall SPID could range from -120 to 240. Two hour windowed last observation carried forward was used as applicable where PI score obtained before a rescue medication replaced PI score for each timepoint within 2 hours following rescue dose.

Secondary Endpoints
Pain Intensity Using a Numeric Pain Rating Scale Utilizing 2-hour Windowed Last Observation Carried Forward (W2LOCF)
24 hours after the first dose
Total Pain Relief
24 hours after the first dose
Pain Relief: Number and Percentage of Subjects With Perceptible and Meaningful Pain Relief
24 hours after the first dose
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
MR-107A-01 15 mg once in a 24-hour periodEXPERIMENTALOral tablet one day of dosing
MR-107A-01 10 mg once in a 24-hour periodEXPERIMENTALOral tablet one day of dosing
MR-107A-01 15 mg twice in a 24-hour periodEXPERIMENTALOral tablet one day of dosing
MR-107A-01 10 mg twice in a 24-hour periodEXPERIMENTALOral tablet one day of dosing
Placebo twice in a 24-hour periodPLACEBO_COMPARATORPlacebo tablet one day of dosing
Interventions
NameTypeDescription
MR-107A-01DRUGOral tablet
PlaceboDRUGOral tablet
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Males and females ≥18 years of age. 2. Requirement for dental surgery for extraction of ≥2 x third molars, at least 1 of which involves partial or complete mandibular bony impaction. 3. Pain Intensity (PI) using a Numeric Pain Rating Scale (NPRS) ≥5 during the 5 hours followi...

Countries:United States
Unlock Eligibility Criteria